Table 3.
Assessment of ACR Paediatric 30, 50, 70, 90, and 100 improvement during anti-TNF treatment in JIA patients (n=188).
| Months of treatment | N | <30% | 30% | 50% | 70% | 90% | 100% | P value* |
|---|---|---|---|---|---|---|---|---|
| 1 | 179 | 38.5% | 61.5% | 35.8% | 16.8% | 5.6% | 3.9% | – |
| 3 | 167 | 18.6% | 81.4% | 65.9% | 27.5% | 16.2% | 15.0% | <0.0000 |
| 6 | 153 | 13.7% | 86.3% | 78.4% | 35.9% | 16.3% | 14.4% | <0.0018 |
| 12 | 141 | 9.5% | 90.5% | 86.5% | 53.9% | 22.7% | 19.1% | <0.0000 |
| 24 | 95 | 5.3% | 94.7% | 88.4% | 62.1% | 34.7% | 26.3% | <0.0003 |
| 36 | 56 | 10.7% | 89.3% | 82.1% | 51.8% | 21.4% | 17.9% | <0.21 |
| 48 | 38 | 2.6% | 97.4% | 92.1% | 68.4% | 23.7% | 23.7% | <0.09 |
*
Paired Wilcoxon test versus previous assessment.